Update on newer neuromuscular blocking drugs.
The development of new non-depolarizing neuromuscular blocking drugs starting with the introduction of the intermediate-acting agents atracurium and vecuronium has made it possible to avoid the use of succinylcholine for elective cases. Recently 4 new drugs have become available; the short-acting mivacurium, the intermediate-acting rocuronium and the 2 long-acting drugs doxacurium and pipecuronium. The pharmacokinetic and pharmacodynamic profile of these drugs are reviewed in this paper.
Holm
H
H
Department of Anaesthesiology, Gentofte Hospital, University of Copenhagen, Denmark.
Ostergaard
D
D
D000328:Adult; D000368:Aged; D000732:Androstanols / Q000493:pharmacokinetics / Q000494:pharmacology; D001279:Atracurium / Q000493:pharmacokinetics / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007546:Isoquinolines / Q000493:pharmacokinetics / Q000494:pharmacology; D000077590:Mivacurium; D003473:Neuromuscular Nondepolarizing Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D017300:Pipecuronium / Q000493:pharmacokinetics / Q000494:pharmacology; D000077123:Rocuronium; D014673:Vecuronium Bromide / Q000493:pharmacokinetics / Q000494:pharmacology
D000732:Androstanols; D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D017300:Pipecuronium; D001279:Atracurium; D000077590:Mivacurium; D014673:Vecuronium Bromide; C049429:doxacurium; D000077123:Rocuronium